MARKETABLE SECURITIES

12 Months Ended

Jul. 31, 2021

Cash and Cash Equivalents [Abstract]

MARKETABLE SECURITIES

4. MARKETABLE SECURITIES

The Company’s marketable securities consist primarily of corporate equities with a quoted market price that are classified as trading securities. On April 13, 2020, in conjunction with the reverse acquisition (see Notes 1 and 3), the Company recorded an initial investment in marketable securities at historical (predecessor) cost basis reflecting an aggregate value of $8,797. Marketable securities are stated at fair value as determined by the closing price of each security at each balance sheet date. Unrealized gains and losses on these securities are included in operations for the applicable period.

As of July 31, 2021, and 2020, the Company’s marketable securities are presented below.

							Change in
							Fair Value
							For the
	Number						Year
	of		Fair Value at				Ended
	Shares		July 31, 2021		July 31, 2020		July 31, 2021
Common Shares of Entest Group, Inc. (ENTI)		66,667	$	340	$	260	$	80
Common Shares of Regen Biopharma, Inc. (RGBP)		29,076,665		393,989		5,814		388,175
Series A Preferred Shares of Regen Biopharma, Inc. (RGBPP)		2,907,666		139,422		4,362		135,060
Total			$	533,751	$	10,436	$	523,315